INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at April 30, 2010

Transparency directive : regulatory news

10/05/2010 17:40

PRESS RELEASE

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT APRIL 30, 2010

Marseilles, May 10, 2010

Pursuant to the article L. 233-8 II of the French " Code de Commerce " and the
article 223-16 of the French stock-market authorities (Autorité des Marchés
Financiers, or "AMF") charter, Innate Pharma SA (the "Company" - Euronext Paris:
FR0010331421 - IPH) releases its total number of shares outstanding as well as
its voting rights as at April 30, 2010:

    Total number of shares outstanding:             37,686,794
    Total number of theoretical voting rights (1):  37,686,794
    Total number of exercisable voting rights (2):  37,598,258

(1) The total number of theoretical voting rights (or "gross" voting rights) is
used as the basis for calculating the crossing of shareholding thresholds. In
accordance with Article 223-11 of the AMF General Regulation, this number is
calculated on the basis of all shares to which voting rights are attached,
including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or "net" voting rights) is
calculated without taking into account the shares with suspended voting rights,
in this case, shares held by the Company in the context of a liquidity
agreement. It is released so as to ensure that the market is adequately
informed, in accordance with the recommendation made by the AMF on July 17,2007.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 79 employees as at March
30, 2010.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code          FR0010331421
Ticker code        IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                   Alize Public Relations
Laure-Hélène Mercier            Caroline Carmagnol
Director, Investor Relations    Phone: +33 (0) 1 42 68 86 43
Phone: +33 (0)4 30 30 30 87     Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com     caroline@alizerp.com

100510_IPH_number_of_shares_as_of_April_30_2010

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at April 30, 2010

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories